ArticleNature cancer2024

A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance.

Christopher E Whitehead et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.